ABVC BioPharma, Inc.
ABVC
$0.911
$0.0354.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -91.08% | 2,289.94% | 1,819.67% | -99.06% | -74.13% |
| Total Other Revenue | 92.28% | -41.51% | -- | -- | -- |
| Total Revenue | -9.09% | 2,348.43% | 1,819.67% | -99.06% | -99.63% |
| Cost of Revenue | -100.00% | -98.99% | -99.73% | -99.50% | -47.55% |
| Gross Profit | 101.46% | 2,939.42% | 274.89% | -98.68% | -142.34% |
| SG&A Expenses | 0.50% | -84.94% | -34.69% | 105.97% | -84.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 3,891.67% | -256.48% | -- | -- | -- |
| Total Operating Expenses | -25.57% | -85.22% | -50.28% | 69.36% | -86.22% |
| Operating Income | 25.65% | 103.08% | 55.48% | -80.69% | 83.70% |
| Income Before Tax | 124.55% | 96.03% | 38.05% | -109.84% | 85.16% |
| Income Tax Expenses | -100.00% | 140.00% | -235.74% | -- | -81.79% |
| Earnings from Continuing Operations | 118.41% | 96.01% | 45.03% | -109.84% | 84.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -68.33% | -203.36% | 402.90% | -34.69% | 187.33% |
| Net Income | 159.82% | 94.38% | 55.26% | -115.66% | 92.12% |
| EBIT | 25.65% | 103.08% | 55.48% | -80.69% | 83.70% |
| EBITDA | 26.60% | 103.42% | 55.95% | -81.24% | 83.91% |
| EPS Basic | 130.31% | 98.17% | 86.93% | 26.73% | 96.10% |
| Normalized Basic EPS | -7.33% | 97.83% | 86.86% | 25.48% | 102.53% |
| EPS Diluted | 129.59% | 97.56% | 86.84% | 26.73% | 96.00% |
| Normalized Diluted EPS | -7.33% | 97.83% | 86.86% | 25.48% | 102.53% |
| Average Basic Shares Outstanding | 97.77% | 205.90% | 242.17% | 194.36% | 101.91% |
| Average Diluted Shares Outstanding | 97.77% | 205.90% | 242.17% | 194.36% | 101.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |